Drug intelligence / Profile preview

formononetin

Development stage
Unknown
Modality
Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Administration
Oral
01

Overview

Formononetin is a naturally occurring isoflavone, primarily found in red clover and the traditional Chinese medicinal herb Astragalus membranaceus. It belongs to the class of 7-hydroxyisoflavones, characterized by a methoxy group at position 4'. Formononetin exhibits a range of biological activities, including antioxidant, anti-inflammatory, anti-cancer, anti-apoptotic, antiviral, antibacterial, and estrogenic effects. Mechanistically, it modulates multiple cellular signaling pathways such as PI3K/AKT, MAPK/ERK/JNK (mitogen-activated protein kinase/extracellular signal-regulated kinase/c-Jun N-terminal kinase), STAT (signal transducer and activator of transcription), and nuclear factor kappa B (NF-κB). In cancer models it induces apoptosis via mitochondrial pathways involving Bax/Bcl-2/caspase-3 proteins and causes cell cycle arrest by regulating cyclins. In neurodegenerative disease models like Alzheimer’s disease it may inhibit amyloid-beta/RAGE interaction and reduce cytokine levels through modulation of Nrf2 signaling. Formononetin has been investigated in clinical trials for postmenopausal osteopenia[1][5][6][8].

Other names
7-hydroxy-4'-methoxyisoflavone
02

Targets

ER (Estrogen receptor)NFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)PI3K (Phosphoinositide-3-kinase regulatory subunit 6)STAT3 (Signal Transducer and Activator of Transcription 3)STAT5A (STAT5)SATB2 (Special AT-rich sequence-binding protein 2)AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)STAT (STAT family)

Beyond the preview

Go deeper on formononetin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on formononetin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call